U.S. FDA and NIH Back Smoking Cessation Innovation, Highlight E-Cigarette Research Needs

Oct.16.2024
U.S. FDA and NIH Back Smoking Cessation Innovation, Highlight E-Cigarette Research Needs
FDA and NIH leaders emphasize the need for smoking cessation treatment research and innovation in a new commentary.

According to a news release posted on the official website of the U.S. Food and Drug Administration (FDA) on October 15, leaders from the National Institutes of Health (NIH) and FDA emphasized the importance of advancing research and development for smoking cessation treatments in a new commentary published in the Annals of Internal Medicine. The authors of the article updated regulatory pathways for smoking cessation treatments and outlined innovative treatment targets, research gaps, and development opportunities. They stressed the crucial role of active participation from clinical physicians, academia, industry, public health agencies, patient groups, and other stakeholders.


Data shows that nearly 500,000 people die from smoking in the United States each year, with over 28 million adults smoking in the country. While most smokers express a desire to quit, only 31% of those intending to quit actually seek counseling or medication treatment. The success rate for quitting smoking each year is less than 8%.


The commentator proposed solutions to these issues, including recommendations from the FDA 2023 Nicotine Replacement Therapy guidelines. In order to inspire innovation in smoking cessation product development, the commentator suggested that in smoking cessation trials, in addition to focusing on abstinence, meaningful endpoints should also be considered, such as clinically significant reduction in smoking, especially if this reduction increases the likelihood of eventual cessation.


The authors also emphasized the urgent need for more in-depth research on e-cigarettes, including long-term health outcomes and rigorous toxicology studies. They also discussed programs being conducted by the NIH and FDA aimed at promoting innovative research on smoking cessation, particularly targeting underrepresented groups in historical research trials.


This commentary was released prior to the joint public meeting of the FDA and NIH on advancing smoking cessation priorities, which is scheduled to take place on October 21 from 9:00 AM to 4:30 PM (Eastern Time).


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BBC survey: over half of secondary teachers in England say vaping is a problem at their school
BBC survey: over half of secondary teachers in England say vaping is a problem at their school
Granville Academy in Swadlincote, Derbyshire, has joined a county pilot overseen by Derbyshire County Council that puts pupils in charge of reducing vaping in school. After reports of pupils stealing vapes, vaping in toilets and using them while walking home, the school found detentions were not effective and shifted to peer-led education sessions, assemblies and health-warning signage.
Feb.05 by 2FIRSTS.ai
Japan Tobacco Launches Limited-Edition “Purple Dusk” Colorway for Ploom AURA, Priced at JPY 2,980
Japan Tobacco Launches Limited-Edition “Purple Dusk” Colorway for Ploom AURA, Priced at JPY 2,980
Japan Tobacco has launched the fourth installment of its limited-color series for the Ploom AURA heated-tobacco device, unveiling “Purple Dusk” . Priced at JPY 2,980 (about USD 18.7, tax included), it goes on limited early sale via official channels from Jan 13, before rolling out to convenience stores and other retail outlets across Japan from Jan 20.
Jan.13 by 2FIRSTS.ai
DTI drafts administrative order proposing an open-pod and e-liquid ban and opens it for public consultation
DTI drafts administrative order proposing an open-pod and e-liquid ban and opens it for public consultation
Department of Trade and Industry’s (DTI) proposed move to restrict harmful vape products to protect young people, but said only a total ban on all vaping and novel tobacco products would effectively safeguard public health. The group warned that limiting rules to certain products such as open pods and e-liquids could create a “dangerous behavioral loophole,” leading users—especially youth—to switch to disposable or closed-system alternatives instead of quitting.
Feb.10 by 2FIRSTS.ai
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opened on February 6, 2026 for the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026. The Bill intends to address illicit trade in tobacco, nicotine pouches and e-cigarettes, which has increased significantly across Tasmania in recent years. It proposes changes to the Public Health Act 1997 to further protect the health of Tasmanians by reducing the sale and supply of illicit tobacco, vaping and other products, and to strengthen existing tobacco control laws.
Feb.06 by 2FIRSTS.ai
2Firsts Breaking | FDA to Hold PMTA Roundtable for Small ENDS Manufacturers, Spotlighting Small Business Applications
2Firsts Breaking | FDA to Hold PMTA Roundtable for Small ENDS Manufacturers, Spotlighting Small Business Applications
The FDA’s Center for Tobacco Products (CTP) will hold a PMTA roundtable on February 10, 2026, for small electronic nicotine delivery systems (ENDS) manufacturers, seeking input on PMTA submission experiences and recommendations for streamlining and improving the review process.
Dec.24
Australia’s TGA Seizes Illicit Vaping Products Worth Over  US$670,000 in Bendigo
Australia’s TGA Seizes Illicit Vaping Products Worth Over US$670,000 in Bendigo
Australia’s Therapeutic Goods Administration (TGA) has seized illicit vaping products with an estimated street value exceeding A$1 million (approximately US$670,000) following an enforcement operation in Bendigo, Victoria.
Dec.24 by 2FIRSTS.ai